We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hypercoagulability After Breast Cancer Surgery (EHC)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00210197
First Posted: September 21, 2005
Last Update Posted: July 26, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Institut Bergonié
  Purpose
The risk of deep venous thrombosis after radical breast surgery is known. The objective of this study is to explore hypercoagulability after radical breast cancer surgery by studying several factors for haemostasis before, during and after surgery. Ultrasound Doppler examination is realised between 24 and 72 hours post-operatively. Hypercoagulability is defined by a significant increasing level of thrombin-antithrombin, D-dimer and the endogen thrombin potential.

Condition Intervention
Breast Cancer Blood Coagulation Disorders Procedure: Blood collection (pre and postoperative): plasma coagulation parameters

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Plasma Coagulation Parameters and Hypercoagulability After Breast Cancer Surgery

Resource links provided by NLM:


Further study details as provided by Institut Bergonié:

Enrollment: 48
Study Start Date: January 2005
Study Completion Date: January 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Breast Cancer
Criteria

Inclusion criteria:

  • Breast cancer
  • mastectomy

Exclusion criteria:

  • thrombophilia
  • anticoagulant treatment
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00210197


Locations
France
Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest
Bordeaux, France, 33076
Sponsors and Collaborators
Institut Bergonié
Investigators
Principal Investigator: Youssef KABBANI, MD Institut Bergonié
  More Information

ClinicalTrials.gov Identifier: NCT00210197     History of Changes
Other Study ID Numbers: IB2005-06
EHC
First Submitted: September 13, 2005
First Posted: September 21, 2005
Last Update Posted: July 26, 2013
Last Verified: October 2007

Keywords provided by Institut Bergonié:
Hypercoagulability
Plasma coagulation parameters
Breast cancer

Additional relevant MeSH terms:
Thrombophilia
Breast Neoplasms
Blood Coagulation Disorders
Hemostatic Disorders
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Hematologic Diseases
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders